124 related articles for article (PubMed ID: 38174674)
21. The Clinical Impact of Solid and Micropapillary Patterns in Resected Lung Adenocarcinoma.
Yanagawa N; Shiono S; Abiko M; Katahira M; Osakabe M; Ogata SY
J Thorac Oncol; 2016 Nov; 11(11):1976-1983. PubMed ID: 27374456
[TBL] [Abstract][Full Text] [Related]
22. Micropapillary and solid subtypes of invasive lung adenocarcinoma: clinical predictors of histopathology and outcome.
Cha MJ; Lee HY; Lee KS; Jeong JY; Han J; Shim YM; Hwang HS
J Thorac Cardiovasc Surg; 2014 Mar; 147(3):921-928.e2. PubMed ID: 24199757
[TBL] [Abstract][Full Text] [Related]
23. Clinical characteristics of T790M-positive lung adenocarcinoma after resistance to epidermal growth factor receptor-tyrosine kinase inhibitors with an emphasis on brain metastasis and survival.
Joo JW; Hong MH; Shim HS
Lung Cancer; 2018 Jul; 121():12-17. PubMed ID: 29858020
[TBL] [Abstract][Full Text] [Related]
24. Adjuvant Chemotherapy Improves the Probability of Freedom From Recurrence in Patients With Resected Stage IB Lung Adenocarcinoma.
Hung JJ; Wu YC; Chou TY; Jeng WJ; Yeh YC; Hsu WH
Ann Thorac Surg; 2016 Apr; 101(4):1346-53. PubMed ID: 26794883
[TBL] [Abstract][Full Text] [Related]
25. Value of adjuvant chemotherapy in patients with resected stage IB solid predominant and solid non-predominant lung adenocarcinoma.
Cao S; Teng J; Xu J; Han B; Zhong H
Thorac Cancer; 2019 Feb; 10(2):249-255. PubMed ID: 30561142
[TBL] [Abstract][Full Text] [Related]
26. Prognostic value of epidermal growth factor receptor gene mutation in resected lung adenocarcinoma.
Deng C; Zhang Y; Ma Z; Fu F; Deng L; Li Y; Chen H
J Thorac Cardiovasc Surg; 2021 Sep; 162(3):664-674.e7. PubMed ID: 32747123
[TBL] [Abstract][Full Text] [Related]
27. Comparison of clinical results between high grade patterns in stage I lung adenocarcinoma.
Jeon HW; Kim YD; Sim SB; Moon MH
Thorac Cancer; 2022 Sep; 13(17):2473-2479. PubMed ID: 35820717
[TBL] [Abstract][Full Text] [Related]
28. Correlation of mutation status and survival with predominant histologic subtype according to the new IASLC/ATS/ERS lung adenocarcinoma classification in stage III (N2) patients.
Russell PA; Barnett SA; Walkiewicz M; Wainer Z; Conron M; Wright GM; Gooi J; Knight S; Wynne R; Liew D; John T
J Thorac Oncol; 2013 Apr; 8(4):461-8. PubMed ID: 23486266
[TBL] [Abstract][Full Text] [Related]
29. First-line epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor alone or with whole-brain radiotherapy for brain metastases in patients with EGFR-mutated lung adenocarcinoma.
Chen Y; Yang J; Li X; Hao D; Wu X; Yang Y; He C; Wang W; Wang J
Cancer Sci; 2016 Dec; 107(12):1800-1805. PubMed ID: 27627582
[TBL] [Abstract][Full Text] [Related]
30. Combination of epidermal growth factor receptor mutation and the presence of high-grade patterns is associated with recurrence in resected stage I lung adenocarcinoma.
Kondo Y; Ichinose J; Ninomiya H; Hashimoto K; Matsuura Y; Nakao M; Ishikawa Y; Okumura S; Satoh Y; Mun M
Interact Cardiovasc Thorac Surg; 2022 Jul; 35(2):. PubMed ID: 35266536
[TBL] [Abstract][Full Text] [Related]
31. Value and significance of brain radiation therapy during first-line EGFR-TKI treatment in lung adenocarcinoma with EGFR sensitive mutation and synchronous brain metastasis: Appropriate timing and technique.
Gu Y; Xu Y; Zhuang H; Jiang W; Zhang H; Li X; Liu Y; Ma L; Zhao D; Cheng Y; Yu Y; Liu P; Qin J; Chen X; Gao J; Wang M; Liang L; Cao B
Thorac Cancer; 2021 Dec; 12(23):3157-3168. PubMed ID: 34651449
[TBL] [Abstract][Full Text] [Related]
32. Solid predominant histology predicts EGFR tyrosine kinase inhibitor response in patients with EGFR mutation-positive lung adenocarcinoma.
Yoshida T; Ishii G; Goto K; Yoh K; Niho S; Umemura S; Matsumoto S; Ohmatsu H; Nagai K; Ohe Y; Ochiai A
J Cancer Res Clin Oncol; 2013 Oct; 139(10):1691-700. PubMed ID: 23974272
[TBL] [Abstract][Full Text] [Related]
33. [Prognostic Analysis of EGFR-TKIs Combined with Gamma Knife in EGFR-mutant Lung Adenocarcinoma with Brain Metastasis].
Chen L; Fu M; Zhou J; Yao Y; Zhou J
Zhongguo Fei Ai Za Zhi; 2019 May; 22(5):312-318. PubMed ID: 31109441
[TBL] [Abstract][Full Text] [Related]
34. Clinical value of the new International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society classification of lung adenocarcinoma.
Guo Z; Yi F; Yin W; Zhang Y; Li Q; Gu Y; Xiao Y; Cao B; Ma L; Liang L
Thorac Cancer; 2017 May; 8(3):159-169. PubMed ID: 28220630
[TBL] [Abstract][Full Text] [Related]
35. Prognosis of epidermal growth factor receptor-mutated stage I lung adenocarcinoma with radiologically solid features.
Hattori A; Matsunaga T; Fukui M; Takamochi K; Suzuki K
Eur J Cardiothorac Surg; 2022 Mar; 61(4):769-777. PubMed ID: 34791156
[TBL] [Abstract][Full Text] [Related]
36. Micropapillary pattern is associated with the development of brain metastases and the reduction of survival time in EGFR-mutation lung adenocarcinoma patients with surgery.
Li C; Shen Y; Hu F; Chu T; Yang X; Shao J; Zheng X; Xu J; Zhang H; Han B; Zhong H; Zhang X
Lung Cancer; 2020 Mar; 141():72-77. PubMed ID: 31955003
[TBL] [Abstract][Full Text] [Related]
37. Prognostic value of the new IASLC/ATS/ERS classification of clinical stage IA lung adenocarcinoma.
Murakami S; Ito H; Tsubokawa N; Mimae T; Sasada S; Yoshiya T; Miyata Y; Yokose T; Okada M; Nakayama H
Lung Cancer; 2015 Nov; 90(2):199-204. PubMed ID: 26341957
[TBL] [Abstract][Full Text] [Related]
38. Activity of pemetrexed and high-dose gefitinib in an EGFR-mutated lung adenocarcinoma with brain and leptomeningeal metastasis after response to gefitinib.
Yuan Y; Tan C; Li M; Shen H; Fang X; Hu Y; Ma S
World J Surg Oncol; 2012 Nov; 10():235. PubMed ID: 23134665
[TBL] [Abstract][Full Text] [Related]
39. Micropapillary Predominance Is a Risk Factor for Brain Metastasis in Resected Lung Adenocarcinoma.
Shigenobu T; Takahashi Y; Masugi Y; Hanawa R; Matsushita H; Tajima A; Kuroda H
Clin Lung Cancer; 2021 Nov; 22(6):e820-e828. PubMed ID: 33992533
[TBL] [Abstract][Full Text] [Related]
40. [Validation of prognostic value of pathological staging in pathological stage Ⅰ lung adenocarcinoma].
Zhang H; Sun FH; Chen ZC; Wang Q
Zhonghua Wai Ke Za Zhi; 2022 Jun; 60(6):580-586. PubMed ID: 35658346
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]